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Abstract Epithelial barrier function is contingent on
appropriate polarization of key protein components. Work
in intestinal epithelial cell cultures and animal models of
bowel inflammation suggested that atypical PKC (aPKC),
the kinase component of the Par3–Par6 polarity complex, is
downregulated by pro-inflammatory signaling. Data from
other laboratories showed the participation of myosin light
chain kinase in intestinal inflammation, but there is paucity
of evidence for assembly of its major target, non-muscle
myosin II, in inflammatory bowel disease (IBD). In
addition, we showed before that non-muscle myosin IIA
(nmMyoIIA) is upregulated in intestinal inflammation in
mice and TNFα-treated Caco-2 cells. Thus far, it is
unknown if a similar phenomena occur in patients with
IBD. Moreover,it isunclearwhether aPKC downregulationis
directly correlated with local mucosal inflammation or occurs
in uninvolved areas. Frozen sections from colonoscopy
material were stained for immunofluorescence with exten-
sively validated specific antibodies against phosphorylated
aPKC turn motif (active form) and nmMyoIIA. Inflammation
was scored for the local area from where the material was
obtained. We found a significant negative correlation between
the expression of active aPKC and local inflammation, and a
significant increase in the apical expression of nmMyoIIA in
surface colon epithelia in inflamed areas, but not in non-
inflamed mucosa even in the same patients. Changes in aPKC
and nmMyoIIA expression are likely to participate in the
pathogenesis of epithelial barrier function in response to local
pro-inflammatorysignals.Theseresultsprovidearationalefor
pursuing mechanistic studies on the regulation of these
proteins.
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Abbreviations
aPKC Atypical PKC, comprises PKCι and PKCζ
isoforms
MLCK Myosin light chain kinase—phosphorylates
the regulatory light chain of myosin II and
promotes myosin II assembly and function
nmMyoIIA Non-muscle myosin IIA—the heavy chains
of this isoform are the products of the MYH9
gene
Par Partition-defective mutants
ROI Region of interest
TNF-α Tumor necrosis factor alpha
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The polarity complex is an evolutionarily conserved set of
proteins involved in the development of cell polarity and the
establishment of tight junctions in epithelia [1]. It comprises
atypical protein kinase C (aPKC, PKCζ and PKCι/λ
isoforms), as well as the orthologs of Caenorhabditis
elegans PARtition-defective mutant proteins [2] Par3 and
Par6 [3]. The polarity complex regulates the formation and
positioning of tight junctions in Drosophila [4]a n d
vertebrate epithelia [5–7]. Like other PKC isoforms, aPKC
is activated by PDK1-dependent phosphorylation in the
activation loop (T403 in PKCι, T410 in PKCζ) followed by
autophosphorylation of the turn motif (T555 PKCι, T563
PKCζ). A phosphorylated turn motif is, therefore, a bona
fide reporter of aPKC active conformation [8].
Mutations in the polarity complex-associated protein
Crumbs are responsible for human retinal dystrophy
(OMIM 600105) [9], and components of the polarity
complex seem to participate in cancer [10], but other
involvement of the polarity complex in human disease has
not been reported so far. Because inflammatory bowel
disease (IBD) pathogenesis includes opening of tight
junctions with increased paracellular permeability in intes-
tinal epithelia [11], we sought to identify changes in the
aPKC–Par complex during inflammation. We found that
aPKC and Par3 are downregulated in human intestinal cells in
tissue culture in response to TNF-α stimulation under
conditions that do not induce apoptosis. Likewise, aPKC
was sharply downregulated in mouse intestinal epithelia in
DSS-induced colitis [12]. The molecular mechanism under-
lying the aPKC downregulation was found to be entirely
posttranslational and mediated by inhibition and down-
regulation of Hsp/Hsc70 chaperones. These are known to
maintain steady-state aPKC levels by rescue from proteaso-
mal degradation [13]. Other groups have reported down-
regulation of Hsp70 chaperones in intestinal inflammation as
well [14]. Altogether, these data lead us to hypothesize that
aPKC may be also downregulated in IBD patients.
It is broadly accepted that pro-inflammatory signaling
results in activation of the long (225 kDa) isoform of
myosin light chain kinase (MLCK) in the intestinal
epithelium [15]. In fact, overexpression of MLCK was
observed in IBD patients [16]. MLCK activity is known to
induce non-muscle myosin II assembly in non-muscle cells,
enhancing the assembly of stress fibers and other cortical
acto-myosin structures [17, 18]. Accordingly, the implica-
tion for MLCK activation is that non-muscle myosin II
assembly is a final effector of pro-inflammatory signaling
on the epithelium resulting in either contractile mechanical
tension applied on the tight junctions or endocytic removal
of tight junction components [19]. From the three non-
muscle myosin II isoforms (nmMyoIIA, nmMyoIIB, and
nmMyoIIC heavy chains products of MYH9, MYH10, and
MYH14, respectively), only nmMyoIIA is associated to
tight junction function [20]. Coincidentally, we found that
shRNA-mediated aPKC knockdown in intestinal cells
results in apical upregulation of nmMyoIIA, but not IIB
or IIC that mimics TNFα stimulation. Likewise, inflamma-
tion in a mouse model also resulted in specific upregulation
of nmMyoIIA in the apical region of colonocytes [12]. In
summary, our current hypothesis is that, in addition to
MLCK activation, inflammatory cytokines induce post-
translational downregulation of aPKC, which can also
result in upregulation of nmMyoIIA. This work was
undertaken to test if these predictions are true in patients
with IBD.
Materials and methods
Bioethical considerations
Biopsies were obtained from patients with IBD, who
provided consent under a University of Miami IBD-
approved protocol for research. Patient identity was known
only to the physician practicing the intervention and not
revealed to the research team that handled codified speci-
mens. Whenever possible, biopsies were taken from
inflamed and uninflamed areas of the colon and terminal
ileum in Crohn's disease (CD) and ulcerative colitis (UC)
patients. Data on colonoscopic severity of inflammation
were recorded at the time of endoscopy.
Tissue processing
The composition of the patient cohort is shown in Table 1.
Biopsies were obtained by colonoscopy and immediately
processed for standard pathology procedures. A small
fraction of the tissues obtained in the colonoscopy was
fixed in 10% trichloroacetic acid for 10 min, a procedure
known to specifically preserve phospho-epitopes [21]. We
have demonstrated that this fixation is appropriate for the
preservation of the phosphorylated turn motif of aPKC
(pT555 PKCι and pT563 PKCζ)[ 13]. It also preserves the
antigenicity of human nmMyoIIA for the antibodies utilized
in this study [12]. The tissues were then transferred to
phosphate-buffered saline and frozen in OCT in isopentane
at melting temperature. Frozen blocks were sectioned and
processed within 3 months. Frozen sections were processed
for immunofluorescence with any of the following anti-
bodies: polyclonal anti-pT555/pT563 aPKC (Abcam, here-
after referred to as pT555) and polyclonal anti-nmMyosin
IIA (isoform specific, Covance), both raised in rabbit, and
the appropriate CY3-coupled affinity-purified secondary
antibody raised in donkey (Jackson Laboratories). For
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published protocol for differential identification of two
primary antibodies raised in the same species [22]. Briefly,
one of the primary antibodies (anti-nmMyoIIa) was mixed
with an approximately equimolecular concentration of
Dylight 488-conjugated affinity-purified Fab fragments of
anti-rabbit IgG raised in goat (Jackson Laboratories). Then
the excess of fluorescent antibody was removed on rabbit
IgG covalently bound to Sepharose 4B. The samples were
first incubated with the other primary antibody (anti-pT555
aPKC), then with a CY3-labeled anti-rabbit antibody, then
with non-immune rabbit IgG, and, finally, with the mixture
described above. All sections were counterstained with
DAPI. The sections were mounted in buffered 10%
polyvinyl alcohol supplemented with 1% propyl gallate
(anti-fading agent), and imaged within 48 h. The antibodies
used in the study were all from the same batch, aliquoted at
the beginning of the procedures. Independent aliquots were
kept frozen and used for each group of tissues (normally
two to four) processed at the same time.
Image acquisition and processing
Image acquisition was performed blindly in a Leica SP5
confocal microscope using a ×63 oil-immersion 1.3
numerical aperture objective. Confocal acquisition param-
eters were determined at the beginning of the study and the
same parameters (e.g., gains, slit aperture, laser intensity)
used for all the images. Confocal optical sections were
0.6 μm thick. Importantly, image acquisition was performed
blindly by block number without information of the
inflammation score. Field selection was performed using
the DAPI channel to identify epithelial structures, without
checking the red channel (for pT555 or nmMyoIIA signal).
All the cells showing apical and basal domains in every
image were used for quantification (i.e., oblique sections
were excluded). The cells per sample ranged 6–42.
Measurement of specific signals was performed also
blindly from inflammation status by another individual. In
all cases regions of interest (ROI) were selected following
preestablished rules as follows. For pT555-aPKC signal,
small ROIs at the apical edge of the cells (determined by
the end of slim background signal) were compared with
ROIs randomly localized in the subapical cytoplasm of the
same cell. For each cell the average pixel intensity (red
channel) was determined in a pair of ROIs and the
cytoplasmic signal (“background”) was subtracted from
the apical signal. For nmMyoIIA signals, the procedure was
similar but one of the ROIs was located at the always
positive basal side of the epithelial cells, so that the average
basal signal was subtracted from the average apical signal.
For each image, ROI pairs were measured in all visible
epithelial cells with identifiable apical/cytoplasmic or
apical/basal regions. Only a few patients were excluded
from the study. Exclusion criteria were as follows: (1) lack
of antibody reactivity in a certain aliquot, with the impossi-
bility of re-sectioning the same block due to block aging or
lack of additional tissue, or (2) missing histopathological or
endoscopy report data to calculate a score.
Inflammation scores
Scores were calculated assigning each block a 0 or 1 value
for each one of the following criteria: (1) physician
colonoscopy image evaluation of the area, tissue presenting
any sign of macroscopic active inflammation was assigned
a 1; (2) histopathological report of the biopsied tissue: any
microscopic sign of active inflammation was assigned a 1;
and (3) infiltration of the section analyzed, as judged by
separation between crypts and density of lymphocytes.
Only the latter was known to the individuals analyzing the
images. The full score was assembled in separate spread-
sheets after the immunofluorescence pixel values in the
images were measured.
Table 1 Patient sample composition and scoring
Ulcerative colitis Crohn's disease
Scores 1–3 Score 0 Scores 1–3 Score 0
Total number of patients 10 5 13 3
Male 2 3 5 2
Female 8 2 8 1
Percent of patients Expected random proportion (%)
Fully consistent scores (0 or 3) 54.8 25
Mismatching score component for 1 or 2 score values:
Macroscopic 19.3 25
Pathology report 6.4 25
Infiltration in the same sample 19.3 25
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The SAS statistical software was used for all statistical
computations and analyses. The data were first assessed for
normality using SAS PROC UNIV ARIA TE. There was no
evidence for non-normality of the data so standard normal
theory statistical procedures were followed. Means and
standard errors were calculated using PROC MEANS.
Difference between clinical score groups was compared in
a one-way analysis of variance using PROC GLM followed
by comparisons to the group with clinical score equal to
zero as the control using Dunnett's test. The same procedure
was used for comparing aPKC expression among different
intestine sites with the exception that pairwise Student t
tests were used following the ANOV A. Correlations were
analyzed using PROC CORR. Significant differences were
tested at alpha=0.05.
Results
Patient population and scoring
Patients were consented among adult individuals diagnosed
with either CD or UC, many of them currently under
standard specific treatment of IBD, and undergoing colono-
scopy as part of their diagnosis and follow-up (Table 1).
Only 8.3% of the patients were smokers. Samples were
taken in parallel and processed for hematoxylin and eosin
stain for standard pathology report, and for the procedures
reported here. To evaluate local inflammation in the mucosa
at the point where the sample was taken, we used three
independent observations: a macroscopic assessment by the
endoscopist, the pathology report of a parallel sample, and
the degree of lamina propria infiltration within the sample
used for immunofluorescence. Importantly, all three param-
eters were fully consistent (scores 0 or 3) in 55% of the
samples (Table 1), well above of the proportion expected by
random coincidence. Furthermore, in cases where one of
the parameters was different from the other two (scores 1
and 2), the histopathology was the mismatching component
of the score only in 6% of the the cases, indicating strong
agreement of this component of the score with at least one
of the other components (Table 1). In 12 patients of the
cohort, we had samples obtained from different regions,
normally inflamed and uninflamed. Accordingly, the scores
matched only in two of these patients, and were different by
two or three in seven of the patients. These differences in
the scores in samples taken from the same patient at the
same time indicate that the inflammation score is represen-
tative of the local status of the mucosa and not an overall
indicator of disease. This was further highlighted by the
fact that the scores were independent of the treatment
(Table 2). For this reason, although some patients were
enrolled in the study with quiescent disease (“controls”), we
preferred to compare samples according to their score, with
score 0 being considered hereafter as controls.
V alidation of the antibodies
The antibodies used in this study were validated by
immunoblot using SDS extracts of Caco-2 human intestinal
epithelial cells. The anti-pT555 PKCι was validated as a
phospho-epitope antibody by treatment of the blots with
either calf intestinal alkaline phosphatase or lambda protein
phosphatase, both of which abrogated antibody recognition
of the specific band. Likewise, the anti-nmMyoIIA was
validated by immunoblot using Caco-2 cell SDS extracts.
The 220-kDa band recognized by the antibody was strongly
downregulated by specific anti-nmMyoIIA shRNA (not
shown). The same batch of antibody, appropriately ali-
quoted, was used throughout the study.
aPKC pT555 signal decreases with inflammation
We first sought to assess the expression of aPKC in its
active conformation in IBD patients. In samples from
patients with score 0, pT555 aPKC signal appeared like
apical “puncta” in most confocal images (Fig. 1, arrows). It
also showed belt-like images around the apical region in
tangential sections (not shown). Finally, it was indistin-
guishable from published images in mouse colon using the
same antibody and fixation [12]. The apical aPKC belts
have been shown to colocalize with tight junction markers
[23]. In patients with scores 1–2, increasing proportions of
epithelial cells either showed faint aPKC pT555 signal or
no signal at all. In samples graded 3, there was no signal in
most of the cells (Fig. 1). To quantify these changes, small
Scores 1–3 Score 0
Immune modifiers 4 1
TNF-α inhibitors 3 1
Immune modifiers and TNF-α inhibitors 2 0
Other treatment 9 3
Patients under treatment/total patients with the same score (%) 78 63
Table 2 Patient treatment and
scoring
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or randomly on the apical border of the cytoplasm when the
puncta could not be distinguished. Similar ROI were sampled
onthesupranuclearcytoplasmtoquantifynon-tightjunctional
signal. Because this signal is identical to background, these
cytoplasmic samples were termed background signal (b ROI,
typical examples in Fig. 1). The difference of the average
pixel values from several randomly selected cells was
averaged per patient and is shown in Fig. 2. Samples with
score 0 showed all positive values, while the differences in
samples with score 3 distributed around a null or slightly
negative value, indicating lack of apical aPKC pT555 signal
in the presence of inflammation. When the pT555 values
were compared, there was a statistically significant difference
among the four inflammation score groups (F3, 28=12.81, p
<0.0001). Each of the higher inflammation score groups (1–
3) had significantly lower pT555 change values than did the
group with inflammation score of zero (t=2.49,p<0.05).W e
could not detect any difference between CD or UC patients.
To determine if there is a natural difference in the distribution
of aPKC signal, we plotted the values from score 0 samples
obtained from the terminal ileum (not used in the rest of the
study), right, transverse, and left colon. No significant
differences were found among the different regions reached
by endoscopy (Fig. 3).
Apical localization of nmMyoIIA increases
with inflammation
In parallel sections from the same samples, we studied the
distribution of nmMyoIIA. In score 0 samples, this protein
distributed to the basolateral domain with faint or no apical
Fig. 1 Representative confocal
immunofluorescence images
of pT555 aPKC signal (red
channel). The arrows point at
positive pT555 aPKC signal in
the apical domain. Yellow boxes
are examples of typical apical
(a ROI) and background (b ROI)
regions of interest used for
quantification of the signal
(Figs. 2 and 3). DAPI (blue
channel) was used to counter-
stain DNA. Bar,1 0μm
Fig. 2 pT555 aPKC signal quantified in IBD patients. Average pixel
intensities in one a ROI and one b ROI per cell were measured in
several (6–42) randomly selected cells per sample. The average of the
differences a ROI–b ROI for each sample was plotted against the
inflammation score. Differences among all score groups were
statistically significant (p<0.0001)
Fig. 3 Distribution of values of pT555 aPKC signal in terminal ileum
(terminal i.), right colon, transverse colon, and left colon. Data are
shown as in Fig. 2, but only from samples with score 0. In this case,
samples obtained from the same patient (in 12 cases) were included.
There were no statistically significant differences among the values for
the different sites
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apical signal. The proportion of cells with apical signal
increasedwiththescore,andmostofthecellsshowedarobust
apical nmMyoIIA signal in score 3 samples (Fig. 4,a r r o w s ) .
Like in the case of aPKC, we quantified pixel values in ROI
on the apical domain (a ROI) or on the basal domain (b ROI).
Unlike for aPKC, the latter do not represent background, but
rather a positive signal relatively constant in all cases (typical
examples shown in Fig. 4). The pixel values were quantified
like in Fig. 3 and the differences are shown in Fig. 5.T h e
group with an inflammation score of 3 had significantly
higher nmMyoIIA values than did the group with a 0
inflammation score (t=2.57, p<0.05).
Correlation between apical expression of nmMyoIIA
and pT555 aPKC signal
The correlation between both variables was studied on a
cell-by-cell basis. We took advantage of the fact that
samples with scores 1–2 often showed mixed populations
of cells with and without pT555 expression (e.g., Fig. 1,
score 2) and also variable levels of apical nmMyoIIA
expression. Additional sections from samples scored 1–2
were double stained for both signals. In Fig. 6,t h ef u l l
image of the epithelium showing the nmMyoIIA signal
(green) and DAPI is shown in the bottom panel. The top
panel shows only the apical border of the same cells in
the red channel (pT555 signal). Some cells were positive
for pT555 (arrows). The apical layer of nmMyoII was
missing or discontinuous in those cells. Conversely, cells
with a robust apical layer of nmMyoIIA (arrows in the
green image) displayed little or no pT555 signal. Images
from 8 different patients were quantified for both signals
as described for Figs. 2 and 5. The values for individual
cells were plotted and showed a strong negative correla-
tion (F=34.6130, p<0.0001; Fig. 7).
Fig. 6 Immunofluorescence colocalization of pT555 aPKC and
nmMyoIIA in samples with intermediate inflammation scores. Section
of colon surface epithelium of a sample with score 2. Top panel
represents the apical border of the same field as the bottom panel and
is aligned. Bar,1 0μm
Fig. 5 nmMyoIIA signal quantified in IBD patients. Average pixel
intensities in one a ROI and one b ROI per cell were measured in
several randomly selected cells per patient. The average of the
differences for each patient was plotted against the inflammation
score. There was a statistically significant difference (p<0.05)
between the score 0 and 3 groups
Fig. 4 Representative confocal immunofluorescence images of
nmMyoIIA signal (red channel). The arrows point at typical
nmMyoIIA signal in the apical domain. Yellow boxes are examples
of typical apical (a ROI) and basal (b ROI) regions of interest used for
quantification of the signal (Fig. 5). DAPI (blue channel) was used to
counterstain DNA. Bar,2 0μm
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We conclude that in IBD patients, steady-state levels of
aPKC in the active conformation decrease with inflamma-
tion while apical expression of nmMyoIIA increases with
inflammation, and that there is a negative correlation
between both signals. While these observations cannot be
used to draw cause–effect conclusions, they are very
consistent with published mechanistic observations in
human intestinal epithelial cells in culture, showing similar
variations in both proteins in response to non-apoptotic
TNF-α stimulation. More importantly, shRNA-mediated
knockdown of aPKC alone was shown to induce accumu-
lation of apical nmMyoIIA [12], raising the possibility that
the observations in the human biopsies reported here may
be representative of a causal relationship. It is of note that
the basolateral distribution of nmMyoIIA observed here is
consistent with localization of nmMyoIIA to stress fibers
[24], to the basal domain of MDCK cells [25], and to
human colon epithelium [26]. It is also consistent with our
previous observation of a constant basal nmMyoIIA signal
with variable apical localization depending on inflammato-
ry status in tissue culture intestinal cells and murine colon
[12]. We conclude that the inflammatory stimulation
modulates mostly the apical expression of nmMyoIIA, with
little or no detectable changes in the basal domain
distribution of this protein.
In regards to nmMyoIIa regulation, inflammation has
been shown to result in upregulation of MLCK, specifically
in the apical domain, in human IBD samples [16], which,
predictably, would result in increased apical non-muscle
myosin II polymerization. The aPKC and MLCK pathways
are, thus, potentially complementary and synergistic.
Because MLCK upregulation occurs at earlier times than
aPKC downregulation in tissue culture cells subjected to
pro-inflammatory signaling [27], it is also possible that
MLCK upregulation may represent an acute response that is
later enhanced by aPKC downregulation. The relationship
between these two pathways, though, remains unknown. At
this time we cannot rule out the possibility that aPKC
downregulation may be a downstream consequence of
MLCK upregulation.
Both aPKC and nmMyoIIA are involved in epithelial
barrier permeability, an important pathophysiologic factor
of IBD: (1) aPKC participates in the organization of tight
junctions [23, 28]; (2) downregulation of aPKC results in a
substantial decrease in transepithelial electrical resistance
and an increase in nonionic fluorescent marker permeability
[12]; and (3) nmMyosin II is necessary for tight junction
disassembly [19]. Therefore, the changes reported here are
likely to participate in the barrier function failure associated
with IBD. Further mechanistic studies of the aPKC pathway
in epithelial inflammatory response are necessary, as it may
present novel therapeutic options. For example, a rescue of
Hsp70 chaperoning activity, inhibited during inflammation
[12], may prevent or ameliorate aPKC downregulation.
Therefore, assessing the relative importance of this pathway
as compared to other known pathways, such as MLCK,
seems to be a reasonable future direction.
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